Treating Breast Cancer Using Antibiotics

Skip to: A Toxin Capable of Halting a Signaling Pathway Achieving Tumour Growth Inhibition The Promise of Drug Repurposing in the Future Triple-negative breast cancer (TNBC) describes the form of the disease that lacks the expression of 3 receptors: estrogen, progesterone, and HER2. Up to 15% of breast cancers are considered to be TNBC, which is correlated with an elevated […]

Continue reading »

Peering into the genome of brain tumor

Researchers at Osaka University have developed a computer method that uses magnetic resonance imaging (MRI) and machine learning to rapidly forecast genetic mutations in glioma tumors, which occur in the brain or spine. The work may help glioma patients to receive more suitable treatment faster, giving better outcomes. The research was recently published in Scientific Reports. Cancer treatment has undergone […]

Continue reading »

Molecular chatter makes for a ‘hot tumor’

A Ludwig Cancer Research study has deciphered a complex molecular conversation between cancer and immune cells that is key to orchestrating the successful invasion of tumors by T cells that kill cancer cells. “We show that two key chemokines, CCL5 and CXCL9, are universally implicated in T cell infiltration across all solid tumors,” said George Coukos, who directs the Lausanne […]

Continue reading »

Team breaks new ground in study of malignant pediatric brain tumor

Scientists are making important progress in the battle against a class of devilishly complex human pediatric brain cancers thanks to a new study from a team of Florida State University students and faculty. Among young children, there’s no brain tumor more common than medulloblastoma. But no specific and effective therapy yet exists for this dangerous disease. Instead, doctors are forced […]

Continue reading »

Suppression of DKK3 protein thwarts pancreatic tumor progression and prolongs survival

Researchers at The University of Texas MD Anderson Cancer Center have shed new light on why pancreatic tumors are so resistant to therapy. The answer may lie in treating a protein found in the scar-type tissue called stroma which often surrounds the tumors. The tumor-associated stroma is comprised mostly of pancreatic stellate cells (PSCs) and its density and possibly the […]

Continue reading »

Study holds promise for new pediatric brain tumor treatment

New research published in Nature Communications from scientists at Huntsman Cancer Institute (HCI) at the University of Utah (U of U), in collaboration with the Stanford University School of Medicine, shows a specific protein regulates both the initiation of cancer spreading and the self-renewal of cancer cells in medulloblastoma, a type of pediatric brain cancer. Among children’s cancers, brain cancer […]

Continue reading »

Study links BAP1 protein to tumor suppression in kidney, eye, bile duct and mesothelioma cancers

Researchers at The University of Texas MD Anderson Cancer Center have shown how BRCA-associated protein 1 (BAP1) serves as a tumor suppressor gene in kidney, eye, bile duct, mesothelioma and other cancers by regulating a form of cell death called ferroptosis, opening up a potential new area of therapy research. Findings from the study, led by Boyi Gan, Ph.D., associate […]

Continue reading »

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells

In an article published July 17, 2018 by Nature Communications, a highly collaborative team of researchers at the Medical University of South Carolina (MUSC) and Ohio State University report that normal breast cells can prevent successful radiation treatment of breast cancer due to dysregulation between tumor suppressors and oncogenes. Tumor suppressors act like brakes that stop cells from undergoing uncontrolled […]

Continue reading »

Researchers engineer T cells to recognize tumor-specific expression patterns, enhancing tumor response

The advent and advancement of T cell therapy, especially chimeric antigen receptor (CAR)-modified T cells, has demonstrated therapeutic potential in treating previously treatment-resistant tumors. However, few CAR targets are absolutely tumor-specific, resulting in “on-target, off-tumor” toxicities that can be severe. Researchers in the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children’s Hospital and Houston Methodist […]

Continue reading »

Newly-approved therapy provides improved quality of life for midgut neuroendocrine tumor patients

Midgut neuroendocrine tumors are a rare type of cancer that develops in the small intestine and colon. Roughly 12,000 people are diagnosed with this disease each year. In January, the United Stated Food and Drug Administration approved Lutathera, a first-of-its-kind peptide receptor radionuclide therapy. The injection consists of a somatostatin analog combined with a radioactive isotope that directly targets neuroendocrine […]

Continue reading »
1 2